文献速递骨质疏松与代谢性骨病

地舒单抗与特立帕肽初始联合与序贯联合治疗高骨折风险的疗效差异

Differential efficacy of initial versus sequential combination of denosumab and teriparatide in osteoporosis at high fracture risk.
PubMed 文献 · Osteoporos Int · 2026-10-02

该回顾性队列研究比较了绝经后高骨折风险女性中,初始联合(地舒单抗起始6个月内加用特立帕肽,n=54)与序贯联合(地舒单抗单药治疗超过6个月后加用特立帕肽,n=25)治疗12个月对骨密度和骨转换标志物的影响。结果显示初始联合组腰椎骨密度增幅显著更大(+13.4% vs +8.3%,P=0.030),且全髋骨密度变化出现关键分歧:初始联合组增加(+6.0%),序贯联合组显著下降(-5.1%,P=0.009)。结论认为初始联合最优,序贯联合需谨慎并可能更适合以椎体风险为主的患者。

要点

  • 初始联合组腰椎骨密度增幅显著高于序贯联合组(+13.4% vs +8.3%,P=0.030)。
  • 序贯联合组全髋骨密度显著下降(-5.1%),而初始联合组增加(+6.0%),组间P=0.009。
  • 序贯联合组骨转换标志物(P1NP和CTX)较初始联合组显著升高(均P<0.01)。

核心结论

  • 初始联合治疗为最优策略;若需序贯联合,应谨慎并可能更适合以椎体风险为主的患者,需进行部位特异性获益风险评估。

研究设计与样本

  • 1年回顾性队列研究,纳入高骨折风险的绝经后女性,初始联合组(地舒单抗起始6个月内加用特立帕肽)n=54,序贯联合组(地舒单抗单药治疗超过6个月后加用特立帕肽)n=25。

主要发现

  • 腰椎骨密度平均增幅初始联合组为+13.4%(95%CI 9.9至22.5%),序贯联合组为+8.3%(95%CI 1.9至9.2%),P=0.030。
  • 全髋骨密度初始联合组增加+6.0%(95%CI -0.5至12.2%),序贯联合组显著下降-5.1%(95%CI -7.1至-3.9%),P=0.009。
  • 序贯联合组骨转换标志物P1NP和CTX较初始联合组显著升高(均P<0.01)。
  • 上述差异在各亚组中一致,无论既往是否使用双膦酸盐或地舒单抗预处理时长。

临床怎么用

  • 对于高骨折风险患者,可优先考虑在地舒单抗起始6个月内联合特立帕肽以优化腰椎和髋部骨密度获益。
  • 若患者已接受地舒单抗单药治疗超过6个月,加用特立帕肽需谨慎评估髋部骨丢失风险,并考虑患者是否以椎体骨折风险为主。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: For patients already on denosumab, adding teriparatide is a suboptimal last resort: it offers limited spinal benefit but carries a significant risk of hip bone loss, mandating a site-specific risk-benefit assessment. BACKGROUND: The management of patients with osteoporosis who exhibit a suboptimal response to denosumab remains clinically challenging. Adding teriparatide to established denosumab therapy is not well defined for high-risk patients in real-world settings. OBJECTIVE: This study aimed to directly compare the 12-month effects on bone mineral density (BMD) and bone turnover markers between an "initial combination" versus "sequential combination" (adding teriparatide to ongoing denosumab) in a cohort of postmenopausal women at high fracture risk. METHODS: In this 1-year retrospective cohort study, patients were assigned to one of two groups based on treatment history: the initial combination group (n = 54), in which teriparatide was initiated within 6 months of starting denosumab, and the sequential combination group (n = 25), in which teriparatide was added after more than 6 months of continuous denosumab monotherapy. The primary outcome was the percent change in lumbar spine (L1-L4) BMD. RESULTS: The mean increase in lumbar spine BMD was significantly greater in the initial combination group (+13.4%; 95% CI 9.9 to 22.5%) compared with the sequential combination group (+8.3%; 95% CI 1.9 to 9.2%; P = 0.030). A critical divergence was observed at the total hip. The initial combination group showed an increase in BMD (+6.0%; 95% CI -0.5 to 12.2%), whereas the sequential combination group experienced a significant decrease (-5.1%; 95% CI -7.1 to -3.9%; P = 0.009). Bone turnover markers (P1NP and CTX) were markedly elevated in the sequential combination group compared to the initial combination group (both P < 0.01). These differential effects were consistent across subgroups, regardless of prior bisphosphonate use or the duration of denosumab pretreatment. CONCLUSION: Initial combination is optimal, while if sequential combination is necessary, it requires caution and may be more suitable for patients with predominant vertebral risk, mandating a site-specific benefit-risk assessment.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Li XP, Chen R, Cheng C, et al. Differential efficacy of initial versus sequential combination of denosumab and teriparatide in osteoporosis at high fracture risk. Osteoporos Int. 2026. PMID: 42823542. doi:10.1007/s00198-026-07979-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。